SARS-CoV-2 (COVID19) yana tashe a duniya, kuma ana sanin allurar rigakafi a matsayin hanya mafi tattalin arziki da inganci don shawo kan cutar ta kwayar cutar.Ƙimar rigakafin al'ada ta al'ada galibi tana amfani da hanyoyin gano ƙwayoyin cuta don tantance tasirin alluran ta hanyar gwaje-gwajen kawar da kai;
Hanyoyin al'ada suna ɗaukar lokaci kuma suna da ƙarancin inganci, yawanci suna ɗaukar kwanaki 2 zuwa 4 don kammala kimantawa, kuma saboda yawancinsu suna amfani da ƙwayoyin cuta masu rai, yana buƙatar aiwatar da shi a cikin matakin biosafety 3 ko sama da dakin gwaje-gwaje, wanda shine lokaci- cinyewa da ƙwazo, kuma yana kawo rashin jin daɗi ga kimanta haɓakawa da tarawa.Sabili da haka, akwai buƙatar gaggawa don hanya mai sauƙi da sauri wanda ya dace da kimantawa na rigakafi masu kariya a cikin yawan jama'a.
Aehealth COVID19 Neutralization Antibody Quantitative Kit Kit ana amfani da shi don gano ƙididdiga na COVID19 na kawar da ƙwayoyin rigakafi a cikin jini, plasma ko duka jinin mutum.Ana iya amfani da shi don saurin ganowa, ƙididdigewa da kuma ganowa sosai a cikin vitro.a asibiti da aka yi amfani da shi a cikin kimantawa na ƙarin tasirin sabon rigakafin cutar coronavirus da kimantawa na kawar da ƙwayoyin cuta a cikin marasa lafiya da aka dawo dasu bayan kamuwa da cuta.
Neutralizing antibodies yana da kyau dakatar da kamuwa da cuta ta hanyar toshe hulɗar tsakanin kwayar cutar ta COVID19 da sel masu masaukin baki.Yawancin ƙwayoyin rigakafi masu lalata suna amsawa ga yanki mai ɗaure mai karɓa (RBD) na furotin mai karu, wanda ke ɗaure kai tsaye ga mai karɓar saman tantanin halitta ACE2.Antibodies-online a halin yanzu yana ba da ƙwayoyin rigakafi guda biyu na neutralizing dangane da clone CR3022.Yayin da yawancin S-protein RBD masu ɗaure ƙwayoyin rigakafi suna gasa don haɗin antigen tare da ACE2, CR3022 epitope ba ya haɗuwa da rukunin ACE2-dauri.
Don haka baya hana daurin antibodies.Yayin da CR3022 da kanta ke ba da sakamako mai rauni kawai, an nuna shi don yin aiki tare da sauran S-protein RBD masu ɗaure ƙwayoyin rigakafi don kawar da COVID19.
Sauƙi aiki
- Babu buƙatar horar da ƙwararru;
- Ƙananan buƙatar samfurin, kawai buƙatar 50 μL;
- Mai jituwa tare da nau'in samfuri da yawa: Serum/Plasma/Jini gabaɗaya.
Babban hankali
- Hankali: 98.95%;
- Musamman: 100%.
Mai inganci
- Lokacin amsawa: Minti 15, Lokacin gwaji: 10s;
- Mai yiwuwa, Faɗin yanayin amfani;
- Ginintan baturi, fiye da gwaje-gwaje 200 ba tare da shigar da wutar lantarki ba.
Abin dogaro
- An tabbatar da gwajin asibiti 3600, gwaje-gwaje 1500 ta samfurin wanda ya kamu da cutar, gwaje-gwaje 900 akan masu allurar rigakafi, gwaji 1200 na mutane na yau da kullun.;
- Ana samun bayanan asibiti daga masu yin allurar ta allurar rigakafin da ba a kunna ba, maganin nucleic acid, rigakafin furotin, da masu kamuwa da ƙwayoyin cuta, mutane na yau da kullun.
- Yanke ƙimar hana darajar 30%.
Ainihin ka'idar da aka yi amfani da ita a cikin wannan kit ɗin ita ce gasa ta immunochromatographic. Layin ganowa (T-line) a kan ɗigon gwajin an rufe shi da angiotensin yana canza enzyme 2 kuma layin sarrafawa (C-line) an rufe shi da goat anti-zomo IgG antibody. conjugate pad an lullube shi da furotin na RBD mai suna COVID19 da kuma rigar rigakafin zomo IgG.Lokacin ganowa, lokacin da samfurin ya ƙunshi antibody ɗin da za a gwada, haɗin gwajin abu a cikin samfurin kuma antigen na fluorescent ya haifar da hadaddun rigakafi kuma hadaddun na rigakafi ba zai iya ɗaure zuwa enzyme mai canza angiotensin 2 wanda ke canzawa akan membrane na nitrocellulose. .Flfluorescent antigen conjugate wanda ba a ɗaure ga antibody da za a gwada zai ɗaure zuwa angiotensin canza enzyme 2 immobilized a kan nitrocellulose membrane don samar da wani ganewa line (T).
- Gwajin gwaji kafin allurar rigakafi;
- Sakamakon saka idanu bayan alurar riga kafi;
- Ƙimar haɗari don kamuwa da cuta ta biyu na mutanen da suka kamu da cutar;
- Ƙimar haɗari ga mutanen al'ada (ciki har da kamuwa da cutar asymptomatic) yiwuwar kamuwa da cuta;
- Gwajin juriya na ƙwayoyin cuta.